$326 Million is the total value of Decheng Capital Management III (Cayman), LLC's 24 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Cue Health Inc. | $57,927,000 | – | 8,980,909 | +100.0% | 17.75% | – | |
| ILMN | New | Illumnia, Inc. | $53,891,000 | – | 154,238 | +100.0% | 16.52% | – |
| ALPN | New | Alpine Immune Sciences, Inc. | $42,233,000 | – | 4,708,288 | +100.0% | 12.94% | – |
| RCUS | New | Arcus BioSciences, Inc. | $27,451,000 | – | 869,790 | +100.0% | 8.41% | – |
| TXG | New | 10x Genomics, Inc. | $23,124,000 | – | 303,984 | +100.0% | 7.09% | – |
| ALBO | New | Albireo Pharma, Inc. | $15,462,000 | – | 518,342 | +100.0% | 4.74% | – |
| EQ | New | Equillium Inc. | $14,009,000 | – | 4,447,308 | +100.0% | 4.29% | – |
| PACB | New | Pacific Biosciences of California, Inc. | $13,321,000 | – | 1,463,872 | +100.0% | 4.08% | – |
| ACET | New | Adicet Bio, Inc. | $11,583,000 | – | 580,000 | +100.0% | 3.55% | – |
| BYSI | New | BeyondSpring Inc. | $10,908,000 | – | 4,958,142 | +100.0% | 3.34% | – |
| New | Sema4 Holings Corp. | $10,496,000 | – | 3,418,929 | +100.0% | 3.22% | – | |
| RXDX | New | Prometheus Biosciences, Inc. | $9,440,000 | – | 250,000 | +100.0% | 2.89% | – |
| New | Aadi Bioscience, Inc. | $8,932,000 | – | 526,329 | +100.0% | 2.74% | – | |
| New | Aura Biosciences, Inc. | $4,620,000 | – | 210,000 | +100.0% | 1.42% | – | |
| CMPI | New | Checkmate Pharamaceuticals, Inc. | $4,253,000 | – | 1,333,254 | +100.0% | 1.30% | – |
| New | Owlet, Inc. | $3,998,000 | – | 898,400 | +100.0% | 1.22% | – | |
| MRSN | New | Mersana Therapeutics, Inc. | $3,608,000 | – | 904,268 | +100.0% | 1.11% | – |
| New | AtriCure Inc. | $3,038,000 | – | 46,259 | +100.0% | 0.93% | – | |
| SCYX | New | Scynexis Inc. | $2,172,000 | – | 555,555 | +100.0% | 0.67% | – |
| TERN | New | Terns Pharmaceuticals, Inc. | $2,121,000 | – | 714,285 | +100.0% | 0.65% | – |
| NBSE | New | NeuBase Therapeutics, Inc. | $1,880,000 | – | 1,000,000 | +100.0% | 0.58% | – |
| NAUT | New | Nautilus Biotechnology, Inc. | $1,302,000 | – | 300,000 | +100.0% | 0.40% | – |
| MASS | New | 908 Devices Inc. | $380,000 | – | 20,000 | +100.0% | 0.12% | – |
| OMIC | New | Singular Genomics Systems, Inc. | $126,000 | – | 20,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.